Unknown

Dataset Information

Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer.


ABSTRACT: Although targeted drugs improved the therapeutic effect of HER2-positive breast cancer, the long-term prognosis was still poor. In this regard, the research and development of antibody-drug conjugates (ADCs) came into being and made a lot of progress. ADCs had the characteristics of both chemotherapeutic agents and targeted agents by combining chemotherapeutic agents and targeted agents through a linker. It not only had a strong anti-tumor effect on HER2-positive breast cancer, but also had certain anti-tumor effects on HER2-low and even HER2-negative patients. In addition, the clinical researches of ADCs combined with immune checkpoint inhibitors (ICIs) therapy had also made a great breakthrough. This review aimed to summarize the clinical progress of ADCs, in particular the two drugs app

SUBMITTER: Yu Y 

PROVIDER: S-EPMC9747846 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature